Lucicebtide (Compound ST101) acts as a selective antagonist of CCAAT/enhancer-binding protein β (C/EBPβ). By binding to the leucine zipper domain of C/EBPβ, it inhibits its dimerization and facilitates its degradation via a ubiquitin-dependent pathway. Lucicebtide halts the cell cycle at the G0/G1 phase and demonstrates cytotoxic effects on cancer cells. Additionally, it shows favorable pharmacokinetic properties and effectively suppresses tumor growth in a mouse model [1].